NCT00686751

Immune Effects of Vitamin D in Hemodialysis Patients

Immunomodulatory Effects of Vitamin D in Chronic Hemodialysis Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Renal Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study to examine whether vitamin D can reduce the activation of the immune system during dialysis. When activated, the immune cells release certain substances, called cytokines, which can be measured from small blood samples. We want to study to what degree the immune system is activated during a regular dialysis treatment and whether the time point of vitamin D administration, either right before the start or right at the end of a dialysis treatment, has an impact on the activation of the immune system.

Conditions

• End Stage Renal Disease
• Hemodialysis
• Inflammatory Response
• Cardiovascular Disease

Interventions

Type	Name	Description
DRUG	paricalcitol	Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.

Timeline

• Start date: 2004-12-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2008-05-30
• Last updated: 2009-05-13

Locations

3 sites across 1 country: United States